ClinicalTrials.gg
RecruitingNCT05775445Updated Feb 21, 2024

Extremes of Coronary Artery Disease and Normality:CAD Extremes

An observational study in Coronary Artery Disease, sponsored by National Heart Centre Singapore. Recruiting at 1 site in Singapore. Open to participants aged 21 Years to 99 Years. Per ClinicalTrials.gov, last updated 2024-02-21.

Sponsored by National Heart Centre Singapore · Observational

How we know

From the registry’s dates

  • Started May 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Other
Enrollment
1,500
Ages
21 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies in Coronary Artery Disease by National Heart Centre Singapore — 5 open to participants now, 7 under way, none of them phase 3. Coronary Artery Disease · National Heart Centre Singapore.

Started
2023
with 1 other
Observational
9 of 11
4 open now
Registered
11th of 11
by date

Among the 11 studies in Coronary Artery Disease by National Heart Centre Singapore, this one is one of 2 that started in 2023, is one of 9 observational ones, and was the 11th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

5 of the 11 studies in Coronary Artery Disease by National Heart Centre Singapore are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 21 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Coronary Artery Disease by National Heart Centre Singapore, or all of them as a file.
02

Study summary

In the field of cardiovascular medicine, there are two differing groups of patients that remain puzzling to clinicians: patients who are not expected to have coronary artery disease (CAD) yet are diagnosed with significant CAD; and those who are have multiple risk factors for CAD but do not have CAD. Bats exhibit unique phenotypes including long lifespans and likely reduced atherosclerosis. Prior work has identified multiple molecular mechanisms of suppressing the activation of inflammasomes, causally linked to atherosclerosis. The investigators hypothesize there are different molecular markers that confer protection or increased risk for CAD, some of which may be similar to bats. Thus, the aim of this study is to identify molecular markers that contribute to or are protective against acute coronary syndrome (ACS) through analyzing the genetics, peripheral blood and atherosclerotic samples from both extreme patient groups using single-cell RNA sequencing and multi-omics approach. In addition, novel anti-atherosclerotic mechanisms and factors from bat studies will be assessed in the human samples. Identification of novel targets that prevent or cause CAD has the potential to aid in the early identification of high-risk patients and development of new therapeutics to combat this growing epidemic. To conduct this study, patients who have undergone a coronary angiogram or a CT coronary angiogram that fall into the both extremes will be recruited and blood samples will be taken for the above analysis. These will be compared to a group of controls (low risk without disease and high risk with disease).

Read the detailed description

Cardiovascular disease (CVD) imposes much mortality and morbidity worldwide. Large population-based studies in Western cohorts (eg. Framingham Heart Study) have formed the foundations of knowledge on the traditional risk factors of cardiovascular disease. Despite this, large gaps in the knowledge of CVD still exist. The clinical conundrum of the extremes of spectrums of CVD continues to baffle clinicians and researchers alike. These include patients without any major cardiovascular risk factors developing acute coronary syndromes (ACS) at a young age. At the other end of the spectrum, there are not uncommonly patients with "full-house" cardiovascular risk factors with minor or no coronary artery disease.

Similar to the phenotype observed in patients with risk factors with little coronary artery disease, the animal bats exhibit unique phenotypes including long lifespans and likely reduced atherosclerosis. A study has shown that the animal bats are able to have plaque-free arteries despite being on a high-fat diet with high plasma cholesterol, which are associated to the development of atherosclerosis. The pathogenesis of atherosclerosis has been linked to inflammasome activation, an intracellular multi-protein complexes that engage in innate immune defenses. An inflammasome typically consists of a sensor that detects pathogens or danger signals, an adaptor, and an effector that initiates pro-inflammatory responses. Aberrations in inflammasomes have been causally linked to numerous diseases, including viral infections, autoimmune, metabolic, and neurodegenerative diseases. However, no effective treatment options have been established thus far. Importantly, multiple molecular mechanisms of suppressing the activation of inflammasomes, causally linked to atherosclerosis, have already been identified in bats. These include dampened sensors and complementary regulation of the effector and downstream cytokine , which could be protective factors of atherosclerosis. These make bats excellent model for anti-atherosclerosis research.

Recent advancements in technology have led to exciting developments in our understanding of the development and prevention of CVD. The use of "big data" and "deep learning", advancements in genomics, metabolomics, proteomics have the possibility of transforming this field. Recent modern prospective population-based studies (eg. The MURDOCK study) aim to reclassify cardiovascular risk using integrated clinical and molecular biosignatures. However, these studies are based primarily in Western populations. Ethnic differences in CVD exist and currently in Asia, there is a dearth of such advanced data. The aim of this study is thus to identify molecular and inflammasome markers that contribute or are protective against ACS using single-cell sequencing and multi-omics approach, and on top of that, using animal models of bats and mice as comparison to humans. Genomic, metabolomics, proteomics, and scRNA-seq may seek to help answer some of this questions and better improve understanding of the development of CVD, potentially developing novel preventive and management strategies.

The specific aims of the project are as follows:

To use advanced genomic, metabolomics, proteomic and single-cell RNA sequencing (scRNA-seq) analysis to understand novel factors influencing the development of coronary artery disease, as well as protection against coronary artery disease

To assess and validate the novel anti-atherosclerotic mechanisms and factors from bat studies in the human samples

To aid in the development of novel preventive and treatment strategies for coronary artery disease.

Study population

The primary focus will be on two patient groups. Group 1 patients will be recruited to study the novel factors influencing the development of coronary artery disease. This will include patients with known significant coronary artery disease but without any significant major cardiovascular risk factors.

Group 2 patients will be recruited to study the novel factors protective against the development of CAD. This will include patients at high risk of developing CAD but no significant CAD

a group of controls will be recruited (Group 3 and Group 4) for comparison (high risk with CAD and low risk with no CAD). Participants from Group 4 may be obtained from existing registries/cohorts.

Patients will be recruited from two sources:

  1. Prospective recruitment from the coronary catheterization lab, CT lab, ward or clinic
  2. Retrospective review of angiograms from the coronary catheterization lab and CT coronary angiogram

Informed consent will be obtained. If the patient is agreeable to take part, clinical data will be obtained from his medical records. The patient will also be required to fill up a questionnaire on the patient's demographics, lifestyle and medical history etc. Blood will be obtained from the patients for genetic, proteomic, and metabolic screening.

Other data will be collected if available as part of routine care.

  1. Demographic and clinical characteristics data
  2. Quality-of-life,
  3. Basic blood investigations. Basic blood investigations include: FBC, renal panel, HbA1c, fasting glucose, LFT, fasting lipids, hs-CRP, ESR, ANA, anti-dsDNA, RF, anticardiolipin antibodies, homocysteine, protein C, protein S, thyroid function tests, etc
  4. Investigations: ECG, CT, Echo, MRI, holter, nuclear imaging, etc
  5. Biobanking and WGS
  6. Metabolomic panel

Clinical Follow-up data:

  1. Mortality data
  2. Stroke/MI/heart failure/Revascularization data
  3. Coronary angiograms and other investigations as part of clinical follow up
  1. Readmissions 3. Quality of life 4. Costs 5. Other clinical outcomes

These will be obtained from medical records or local, hospital or national databases.

03

Conditions studied

  • Coronary Artery Disease
04

Who can participate

Ages eligible
21 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Coronary Artery Disease patients with high risk factors/ low risk factors No Coronary Artery disease but with high risk factors

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Group 1:

  1. Evidence of significant CAD a. Coronary angiogram or CT coronary angiogram with documented stenosis >=50% in left main or >=70% in major epicardial vessel or major branches (LAD, LCX, RCA)

    AND all of the following

  2. Age \</= 45 for males and \</= 50 for females
  3. Absence of diabetes mellitus
  4. Absence of tobacco use
  5. No prior CVA or PAD

Group 2

  1. Evidence of significant CAD

    1. Coronary angiogram or CT coronary angiogram with documented stenosis >=50% in left main or >=70% in major epicardial vessel or major branches (LAD, LCX, RCA)

    AND all of the following

  2. Age \</= 45 for males and \</= 50 for females
  3. Absence of diabetes mellitus
  4. Absence of tobacco use
  5. No prior CVA or PAD

Group 3 1. Evidence of significant CAD with one of the following:

  1. age>65
  2. Diabetes mellitus
  3. End Stage Renal Failure (ESRF)
  4. Framingham risk score >10%

Group 4

  1. No evidence of significant CAD and all of the following
  1. Age \<55 for males, \<65 for females
  2. Absence of diabetes mellitus
  3. Absence of CKD
  4. Absence of tobacco use

Exclusion criteria

Exclusion Criteria:

  1. Prior history of cancer (excludes pre-cancerous lesions)
  2. Expected less than 1 year
  3. Known disease
  4. Psychiatric illness
  5. Chronic lung disease requiring long term medications or oxygen
  6. Chronic infective disease, including tuberculosis, and C; and
  7. Inability to comply with study protocol
  8. Any other acute or chronic medical or physical condition deemed by the investigator to affect study outcomes
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Observational model
Case-control
Time perspective
Other
Enrollment
1,500 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Group 1 (significant CAD, low risk factors)

    1. Evidence of significant CAD a. Coronary angiogram or CT coronary angiogram with documented stenosis \>=50% in left main or \>=70% in major epicardial vessel or major branches (LAD, LCX, RCA) AND all of the following 2. Age \</= 45 for males and \</= 50 for females 3. Absence of diabetes mellitus 4. Absence of tobacco use 5. No prior CVA or PAD

    Procedure: Blood draw

  • Group 2 (minor CAD, high risk factors)

    1. No evidence of significant CAD a. Coronary angiogram or CT coronary angiogram with \<50% stenosis in major blood vessel/branch 2. No prior history of clinical CAD, PAD or CVA with one of the 3. Age \>65 with 1. Diabetes mellitus \>5years; or 2. End Stage Renal Failure (ESRF), regardless of duration or 3. Framingham risk score \> 10% 4. Diabetes \>10 years 5. End Stage Renal Failure (ESRF) \> 5 years 6. Age \>80

    Procedure: Blood draw

  • Group 3 (signifcant CAD, high risk factors)

    1. Evidence of significant CAD with one of the following: 1. age\>65 2. Diabetes mellitus 3. End Stage Renal Failure (ESRF) 4. Framingham risk score \>10%

    Procedure: Blood draw

  • Group 4 Control group

    1. No evidence of significant CAD and all of the following: 1. Age \<55 for males, \<65 for females 2. Absence of diabetes mellitus 3. Absence of CKD 4. Absence of tobacco use

    Procedure: Blood draw

Interventions

  • ProcedureBlood draw

    2 6ml blood tubes will be collected from patient

06

What researchers measure

Primary outcomes

  1. Using sequencing analysis to develop treatment to protect against Coronary artery disease

    To use advanced genomic, metabolomics, proteomic and single-cell RNA sequencing (scRNA-seq) analysis to understand novel factors influencing the development of coronary artery disease, as well as protection against coronary artery disease

    Time frame: 5 years

  2. Develop treatment for Coronary artery disease

    To aid in the development of novel preventive and treatment strategies for coronary artery disease

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Paulin N, Viola JR, Maas SL, de Jong R, Fernandes-Alnemri T, Weber C, Drechsler M, Doring Y, Soehnlein O. Double-Strand DNA Sensing Aim2 Inflammasome Regulates Atherosclerotic Plaque Vulnerability. Circulation. 2018 Jul 17;138(3):321-323. doi: 10.1161/CIRCULATIONAHA.117.033098. No abstract available. PubMed 30012706 ↗
  • Widmaier EP, Gornstein ER, Hennessey JL, Bloss JM, Greenberg JA, Kunz TH. High plasma cholesterol, but low triglycerides and plaque-free arteries, in Mexican free-tailed bats. Am J Physiol. 1996 Nov;271(5 Pt 2):R1101-6. doi: 10.1152/ajpregu.1996.271.5.R1101. PubMed 8945941 ↗
  • Alwan A, Maclean DR, Riley LM, d'Espaignet ET, Mathers CD, Stevens GA, Bettcher D. Monitoring and surveillance of chronic non-communicable diseases: progress and capacity in high-burden countries. Lancet. 2010 Nov 27;376(9755):1861-8. doi: 10.1016/S0140-6736(10)61853-3. Epub 2010 Nov 10. PubMed 21074258 ↗
  • Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, Abela GS, Franchi L, Nunez G, Schnurr M, Espevik T, Lien E, Fitzgerald KA, Rock KL, Moore KJ, Wright SD, Hornung V, Latz E. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010 Apr 29;464(7293):1357-61. doi: 10.1038/nature08938. Erratum In: Nature. 2010 Jul 29;466(7306):652. PubMed 20428172 ↗

Individual participant data

Plan to share: No — Participants will be assigned a research ID that only research coordinator and team knows

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for Dec 2027, 55 months after the start.

Of 637 non-industry observational studies under Coronary Artery Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 122. This study's planned 55 months is above that.

Counting every sponsor, half of 762 studies reached it within 41 months; a quarter within 21 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2023
First posted
Mar 20, 2023
StartActual
May 30, 2023
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Feb 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05775445
Lead sponsor
National Heart Centre Singapore
Collaborators
Duke-NUS Graduate Medical School
Responsible party
Sponsor
First posted
Mar 20, 2023
Start date
May 30, 2023
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Feb 21, 2024

Study contacts

Aishah Toh
Contact
aishah.toh@nhcs.com.sg
67042282 ext. 67042282
Pei Yi Ho
Contact
ho.pei.yi@nhcs.com.sg
67042234 ext. 67042234
Khyung Keong Yeo
principal investigator · National Heart Centre

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion